Once-daily USL255 as adjunctive treatment of partial-onset seizures: Randomized phase III study

Epilepsia

Volumn 55, Issue 7, 2014, Pages 1077-1087

  Chung, Steve S ^a   Fakhoury, Toufic A ^b   Hogan, R Edward ^c   Nagaraddi, Venkatesh N ^d   Blatt, Ilan ^e   Lawson, Balduin ^f   Arnold, Stephan ^g   Anders, Bob ^h   Clark, Annie M ^h   Laine, Dawn ^h   Meadows, R Shawn ⁱ   Halvorsen, Mark B ^h  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Bluegrass Community Research   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d Neurological Clinic of Texas   (United States)

^e SHEBA MEDICAL CENTER   (Israel)

^f HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^g NeuroCenter Nymphenburg   (Germany)

^h Upsher Smith Laboratories Inc   (United States)

ⁱ Pharmaceutical Product Development   (United States)

Author keywords

Antiepileptic drug; Epilepsy; Extended release; Topiramate

Indexed keywords

ANTIEPILEPTIC DRUG; EPILEPSY; EXTENDED RELEASE; TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904389380     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12660     Document Type: Article

References (38)

1. Cramer JA, Glassman M, Rienzi V,. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3: 338-342.
2. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians. Epilepsy Behav 2008; 13: 316-322.
3. Begley CE, Annegers JF, Lairson DR, et al. Estimating the cost of epilepsy. Epilepsia 1999; 40 (Suppl. 8): 8-13.
4. Werz MA,. Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag 2008; 4: 1035-1046.
5. Leppik IE, Hovinga CA,. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia 2013; 54: 28-35.
6. Janssen Pharmaceuticals Inc. Topamax prescribing information. Titusville, NJ: Janssen Pharmaceuticals Inc.; 2012.
7. Halvorsen MB, Braun TL, Clark AM, et al. USL255, extended-release topiramate, demonstrates dose-proportional pharmacokinetics and tolerability over a wide dosing range in healthy subjects. Epilepsia 2013; 54: 62.
8. Lambrecht LJ, Shekh-Ahmad T, Todd WM, et al. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 2011; 52: 1877-1883.
9. Bialer M, Shekh-Ahmad T, Braun TL, et al. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013; 54: 1444-1452.
10. Food and Drug Administration (FDA). Qudexy XR NDA Approval, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/ 205122Orig1s000ltr.pdf. Accessed March 17, 2014.
11. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
12. DiVentura B, French J, Anders B, et al. Use of investigator training to improve seizure classification in PREVAIL-a phase 3, global study evaluating USL255, once-daily extended-release topiramate, in adults with partial-onset seizures. Epilepsy Curr 2014; 14: 397.
13. Bowker AH,. A test for symmetry in contingency tables. J Am Stat Assoc 1948; 43: 572-574.
14. Fraunfelder FW, Fraunfelder FT, Keates EU,. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004; 111: 109-111.
15. French J, DiVentura B, Posner H, et al. Real-time central patient review improved quality in once-a-day trial of pregabalin forpartial epilepsy in adults. 15th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT), Bethesda, MD, USA.
16. Vogelsong B, French J, Brodie M,. Assessment of seizure classification in multinational, multicenter antiepileptic drug trials. Epilepsy Curr 2011; 11 (Suppl. 1): 111.
17. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-1317.
18. Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007; 69: 1610-1618.
19. Sperling MR,. The consequences of uncontrolled epilepsy. CNS Spectr 2004; 9: 98-101, 106-109.
20. Berto P,. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 2002; 20: 1039-1059.
21. Privitera M, Ficker DM,. Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial. Epilepsy Behav 2004; 5: 841-846.
22. Cramer JA, Mintzer S, Wheless J, et al. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 2010; 10: 885-891.
23. Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-287.
24. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010; 51: 958-967.
25. Beydoun A, D'Souza J, Hebert D, et al. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009; 9: 33-42.
26. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
27. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35: 113-121.
28. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684-1690.
29. Guberman A, Neto W, Gassmann-Mayer C,. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183-189.
30. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79: 589-596.
31. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54: 117-125.
32. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-453.
33. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010; 75: 1817-1824.
34. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011; 76: 1555-1563.
35. Davis KL, Candrilli SD, Edin HM,. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008; 49: 446-454.
36. Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71: 1572-1578.
37. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527-539.
38. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.